Former GSK CEO Sir Andrew Witty, and his former drug development chief, Moncef Slaoui have both lined up new jobs as life science investors. The announcements yesterday are part of a growing trend ...

GlaxoSmithKline’s (GSK) former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.

Helmsley’s expected windfall comes after Andrew Witty stepped down last month following ... Some of his top hires were former colleagues from GSK, the London-based pharmaceutical company ...

Chief Executive Officer Andrew Witty stood up in the front and offered ... Witty, who was earlier CEO of the drugmaker GlaxoSmithKline (now known as GSK), took over UnitedHealth in 2021.

Chief Executive Officer Andrew Witty stood up in the front and offered an encouraging message: Business was good. He was optimistic about the company’s prospects in the coming year. A trio of ...

After years of picking up royalties on GSK’s asthma and COPD inhaler Trelegy, Theravance Biopharma is opting to sell its remaining financial interest to GSK in exchange for a cash reward of $225 ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the developer of the treatment, Scynexis, has resumed a phase 3 study in another use.

Both companies viewed the early end to the PIVOT-PO trial as a positive development, with GSK saying it would work with US regulatory authorities to move the treatment forward in 2025. GSK and Spero ...